EGFR and glioblastoma: A gene level biomarker, LOH of which is associated with poor survival outcomes for both anaplastic astrocytomas and GBM (92). The lost or inactive state of PTEN has been linked to the resistance of targeted EGFR inhibitors in GBM (93)